About Antlia Bioscience
Antlia Bioscience is a private company based in Encinitas, California. It has reported $6,887,000 raised in three offerings on Form D since October 2020. Its chief executive is Ankit Mahadevia.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 22, 2026 | Jun 5, 2026 | $6,000,000of $20.0M target | 3 | $2.0M | EquityRule 506(b) | Form D ↗ |
| Apr 13, 2022 | Apr 26, 2022 | $680,000of $2.5M target | 10 | $68,000 | Equity, Securities on exerciseRule 506(b) | Form D ↗ |
| Oct 14, 2020 | Oct 23, 2020 | $207,000of $600K target | 7 | $29,571 | Debt, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, three offerings | $6,887,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Antlia Bioscience's Form D filed Jun 5, 2026.
AM
Ankit Mahadevia
Chief Executive Officer and director
BA
Ben Auspitz
Director
MT
Martin Taylor
Director
CE
Carlos Echeverria
Director
NS
Nihal Sinha
Director
BJ
Brian Johnson
Executive officer and director
Also a chief executive officer and director at Caradon Therapeutics.